BioNTech reports overall survival benefit in late-stage lung cancer trial
BioNTech said its Phase 3 PRESERVE-003 trial showed a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.